Wacker Biotech is your all-in-one CDMO partner of choice for the production of advanced nucleic acid therapeutics and vaccines, as well as recombinant proteins and live biotherapeutic products (LBP) based on microbial systems. We offer mRNA production across the full manufacturing chain, from plasmid DNA (pDNA) to mRNA to LNP formulation, for vaccines and advanced gene therapies. Offerings include diverse solutions ranging from pDNA supply using our PLASMITEC^® platform, to process development, transfer of mRNA-based processes, and GMP manufacturing for clinical and commercial supply. Additionally, customers benefit from a broad spectrum of LNP formulations for their mRNA-based product.

In June 2024, we completed construction and opened a state-of-the-art mRNA competence center in Halle, Germany, greatly expanding our mRNA production capacity. This complements existing capabilities at our global GMP facilities in Amsterdam, Halle and San Diego. Also complementing these sites is a dedicated R&D center in Munich, Germany with scientific experts leading innovations in pDNA manufacturing, mRNA production, LNP formulation, and analytical development.

Wacker Biotech is a wholly owned subsidiary of 110-year-old Wacker Chemie AG. For more information, visit: wacker.com/biologics.